FDA workshop on topical antifungals and tretinoid products
Scheduled for Nov. 16 from 8:30 am to 5 pm in conference room D of the FDA Parklawn Building. Participants, including experts in the field of topical anti-fungal and tretinoid products (Ortho's Retin-A) and FDA officials, will discuss proposed protocols and guidelines for bioequivalence studies for the nonsystemically asborbed products. The agency is also considering inviting reps from the Generic Pharmaceutical Industry Association, the National Association of Pharmaceutical Manufacturers, and the Pharmaceutical Manufacturers Association to provide comments. Notice of the meeting will soon appear in the Federal Register.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.